Answers are grounded in this paper and cite their sources.
Background: A positive respiratory syncytial virus (RSV) test establishes viral detection but does not necessarily explain disease severity, identify clinically relevant coinfections, or predict disease progression. Multiplex molecular testing, viral load assessment, and host-response biomarkers may provide additional information, yet their ability to improve clinical assessment and decision-making in children with RSV infection remains uncertain. Aim: This narrative review examines the clinical value of advanced diagnostic tools in pediatric RSV infection, addressing both antimicrobial stewardship through reducing unnecessary antibiotic use and acute clinical decision-making through pathogen identification and severity stratification, with a focus on multiplex polymerase chain reaction (PCR), viral load assessment, and inflammatory biomarkers. Results: Multiplex PCR broadens etiological characterization by detecting additional respiratory pathogens, but viral co-detection is not consistently associated with greater disease severity, while bacterial detection must be distinguished from colonization and clinically significant coinfection. Cycle threshold (Ct) values are assay-dependent proxies for the amount of target viral RNA rather than standardized quantitative viral-load measurements and have been associated with disease severity and respiratory support requirements in some pediatric cohorts. However, inter-assay variability, sampling time, and prolonged RNA shedding limit their reliability as independent prognostic indicators. Host-response biomarkers address a different diagnostic dimension. Procalcitonin (PCT) may be more informative for invasive bacterial infection than for localized bacterial coinfection, whereas C-reactive protein (CRP) lacks sufficient specificity. Leukocyte-derived indices, including neutrophil-to-lymphocyte (NLR) and monocyte-to-lymphocyte (MLR) ratios, have been associated with severity in selected RSV cohorts, but their incremental prognostic utility remains unvalidated. Across these approaches, greater analytical sensitivity or more extensive biological information does not necessarily translate into greater clinical utility. Conclusions: The central challenge in pediatric RSV diagnostics is not simply detecting additional pathogens or measuring more biological parameters, but determining which findings meaningfully contribute to patient assessment, risk stratification, and antibiotic decision-making. Current evidence does not support the isolated use of molecular co-detection, Ct values, or inflammatory biomarkers to establish bacterial coinfection or predict disease severity. Integrated diagnostic strategies combining pathogen detection, viral burden, host-response markers, and clinical findings may improve clinical decision-making, support appropriate antibiotic use, and reduce unnecessary antibiotic prescriptions. Future studies should evaluate their impact on patient management and antimicrobial stewardship.
No takes yet. Share an insight, caveat, or question.
Chirvasa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: